Cell Growth & Differentiation, Vol 7, Issue 11 1501-1506, Copyright © 1996 by American Association of Cancer Research

ARTICLES

A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780

H Huynh, XF Yang and M Pollak
Lady Davis Research Institute, Jewish General Hospital, Montreal, Quebec, Canada.

Insulin-like growth factors (IGFs) are potent mitogens for breast cancer cells. Although IGF-binding proteins (IGFBPs) are known to regulate access of IGFs to IGF receptors, their precise biological actions are poorly defined. We observed that the potent antiestrogen ICI 182780 (ICI) increased IGFBP-5 mRNA by 2-3-fold in 9,10-dimethyl-1,2-benzanthracene-induced mammary tumors in vivo. In vitro studies showed that growth inhibition of MCF-7 human breast cancer cells induced by ICI was associated with increased transcription of the IGFBP-5 gene, increased IGFBP-5 mRNA abundance, and increased IGFBP-5 protein accumulation in the conditioned medium. Growth stimulation following estradiol exposure was associated with opposite effects. An IGFBP-5 antisense oligodeoxynucleotide significantly decreased IGFBP-5 accumulation in conditioned media and enhanced MCF-7 cell DNA synthesis. Furthermore, this antisense oligodeoxynucleotide attenuated both antiestrogen-induced IGFBP-5 accumulation and antiestrogen-induced growth inhibition. These data demonstrate that estradiol down-regulates and ICI up-regulates an autocrine IGFBP-5 growth inhibitory pathway in MCF-7 cells and suggest that IGFBP-5 plays a role in modulation of proliferation of breast cancers by estrogens and antiestrogens.

This article has been cited by other articles:

				B. Y. Ahn, A. N. Elwi, B. Lee, D. L. N. Trinh, A. C. Klimowicz, A. Yau, J. A. Chan, A. Magliocco, and S. W. Kim Genetic Screen Identifies Insulin-like Growth Factor Binding Protein 5 as a Modulator of Tamoxifen Resistance in Breast Cancer Cancer Res., April 15, 2010; 70(8): 3013 - 3019. [Abstract] [Full Text] [PDF]

				S. R. Plymate, K. Haugk, I. Coleman, L. Woodke, R. Vessella, P. Nelson, R. B. Montgomery, D. L. Ludwig, and J. D. Wu An Antibody Targeting the Type I Insulin-like Growth Factor Receptor Enhances the Castration-Induced Response in Androgen-Dependent Prostate Cancer Clin. Cancer Res., November 1, 2007; 13(21): 6429 - 6439. [Abstract] [Full Text] [PDF]

				J. F. Smyth, C. Gourley, G. Walker, M. J. MacKean, A. Stevenson, A. R. W. Williams, A. A. Nafussi, T. Rye, R. Rye, M. Stewart, et al. Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use of Letrozole in Estrogen Receptor-Positive Patients Clin. Cancer Res., June 15, 2007; 13(12): 3617 - 3622. [Abstract] [Full Text] [PDF]

				G. Walker, K. MacLeod, A. R.W. Williams, D. A. Cameron, J. F. Smyth, and S. P. Langdon Insulin-like Growth Factor Binding Proteins IGFBP3, IGFBP4, and IGFBP5 Predict Endocrine Responsiveness in Patients with Ovarian Cancer Clin. Cancer Res., March 1, 2007; 13(5): 1438 - 1444. [Abstract] [Full Text] [PDF]

				J. Beattie, G. J. Allan, J. D. Lochrie, and D. J. Flint Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis Biochem. J., April 1, 2006; 395(1): 1 - 19. [Abstract] [Full Text] [PDF]

				M. Becker, A. Sommer, J. R. Kratzschmar, H. Seidel, H.-D. Pohlenz, and I. Fichtner Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM Mol. Cancer Ther., January 1, 2005; 4(1): 151 - 170. [Abstract] [Full Text] [PDF]

				A. J. Butt, K. A. Dickson, F. McDougall, and R. C. Baxter Insulin-like Growth Factor-binding Protein-5 Inhibits the Growth of Human Breast Cancer Cells in Vitro and in Vivo J. Biol. Chem., August 8, 2003; 278(32): 29676 - 29685. [Abstract] [Full Text] [PDF]

				R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF]

				J. M. Chan, M. J. Stampfer, E. Giovannucci, P. H. Gann, J. Ma, P. Wilkinson, C. H. Hennekens, and M. Pollak Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study Science, January 23, 1998; 279(5350): 563 - 566. [Abstract] [Full Text]